Study the efficacy and safety of fentanyl patches on QOL/ADL in patients with chronic pai
Phase 4
- Conditions
- patients with chronic pain
- Registration Number
- JPRN-UMIN000006429
- Lead Sponsor
- Kawasaki Medical School,Department of Orthopedics, Traumatology and Spine Surgery
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 5
Inclusion Criteria
Not provided
Exclusion Criteria
Patients with hypersensitivity to opioids Patients with a history of opioid abuse Patients with respiratory dysfunction such as chronic lung disease Patients with asthma Patients with severe cardiac dysfunction Patients with severe liver and renal dysfunction Intracranial hypertension, patients with impaired consciousness Eczema at the site of drug patch testing, patients with atopic dermatitis, etc. Patients with fever above 40 degree was observed Pregnant women, patients might have been pregnant or nursing mothers Within two days before starting the test, patients who are scheduled to be administered to patients receiving an opioid receptor antagonist such as pentazocine or buprenorphine.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method VAS: Visual Analogue Scale
- Secondary Outcome Measures
Name Time Method SF-36 Patient satisfaction (at the end of the test is performed out of 5) Adverse event